2017
DOI: 10.1016/j.clinbiochem.2017.02.017
|View full text |Cite
|
Sign up to set email alerts
|

Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA

Abstract: Urinary cell-free (cf) DNA holds great potential as a completely noninvasive form of liquid biopsy. Knowledge of the composition of cfDNA by tissue of origin is useful for guiding its clinical uses. We conducted a global survey of urinary cfDNA composition using genomewide bisulfite sequencing. While previous studies focused on detecting cfDNA from a single source at a time, genomewide tissue specific methylation signatures allow us to simultaneously deduce the proportional contribution from each contributing … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

3
62
2

Year Published

2017
2017
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 65 publications
(67 citation statements)
references
References 31 publications
3
62
2
Order By: Relevance
“…In one study, a method for deconvoluting genome-wide bisulfite sequencing data was developed to produce ‘tissue methylation maps’ of cfDNA for pregnant women, cancer patients, transplantation patients, and healthy subjects, revealing percentage contributions by different tissues [135]. The clinical potential of this method has been substantiated by other studies [[182], [183], [184]], and has provided some insight regarding the composition, degradation and variation of cfDNA in urine [185]. However, some major drawbacks of bisulfite sequencing is the high level (84–96%) of degradation of input DNA during the bisulfite conversion process [186], high costs, and the recovery of limited information due to the low abundance of CpGs in the genome.…”
Section: Utility Of Cfdna In Clinical Oncologymentioning
confidence: 99%
“…In one study, a method for deconvoluting genome-wide bisulfite sequencing data was developed to produce ‘tissue methylation maps’ of cfDNA for pregnant women, cancer patients, transplantation patients, and healthy subjects, revealing percentage contributions by different tissues [135]. The clinical potential of this method has been substantiated by other studies [[182], [183], [184]], and has provided some insight regarding the composition, degradation and variation of cfDNA in urine [185]. However, some major drawbacks of bisulfite sequencing is the high level (84–96%) of degradation of input DNA during the bisulfite conversion process [186], high costs, and the recovery of limited information due to the low abundance of CpGs in the genome.…”
Section: Utility Of Cfdna In Clinical Oncologymentioning
confidence: 99%
“…We used unsupervised 22 hierarchical clustering of the cfDNA cell and tissue type composition for all samples in which BK 23 virus (RGE > 10 3 ) or a potential bacterial uropathogen was detected (RGE > 0.09, the lowest 24 corresponding relative genomic abundance observed in the comparison to clinical metrics 25 described above). This analysis, shown in figure 4d, summarizes the major layers of information 26 that are made accessible with the cfDNA assay reported here, and shows that the cfDNA tissue 27 and cell type composition is associated with the presence or absence of viral or bacterial 28 uropathogens. 29 30 31…”
mentioning
confidence: 71%
“…compared CpG methylation profiles of each tissue group in a one-versus-one approach and found 25 91,275 DMRs, with an average length of 453 base pairs (bp). Principal component analysis (PCA) 26 of the methylation density measured across all DMRs revealed global tissue-specific clustering, 27 with three heterogeneous clusters representing blood, gut and a diverse group of other solid organ 28 tissues ( Fig.1d, Supplemental Fig. 1).…”
mentioning
confidence: 99%
See 2 more Smart Citations